BACKGROUND:
During the past two decades the number of injections that are required per office visit to fulfill the recommended childhood immunization schedule has increased dramatically.
METHODS:
By reviewing the literature, the Principles associated with pediatric combination vaccines are discussed, and practical issues related to their use in clinical practice are evaluated.
RESULTS:
The ideal combination vaccine is safe, effective and easy to store and use, and its antigenic components fit within the recommended immunization schedule. The ideal combination is associated with fewer adverse reactions than the separately administered antigens, with improved efficacy and higher immune responses compared with its component vaccines. An acceptable combination vaccine must provide comparable efficacy and safety to its component vaccines. Although there are a limited number of combination vaccines already available [diphtheria-tetanus-pertussis, inactivated poliovirus vaccine (IPV) and measles-mumps-rubella], effort is being focused on combining these vaccines with other routine vaccines of infancy including Haemophilus influenzae type b (Hib) and hepatitis B vaccine (HepB). Currently under review by the Food and Drug Administration are diphtheria-tetanus-acellular pertussis (DTPa)-HepB-IPV and DTPa-Hib-IPV combination vaccines, and two DTPa-HepB-IPV-Hib vaccines have been licensed in Europe. As more combination vaccines become available, issues such as interchangeability and administration of extra doses are raised; however, it is important not to miss a vaccination opportunity.
CONCLUSIONS:
The number of injections required to fulfill the recommended childhood immunization schedule at each visit creates problems for patients and practitioner, sometimes risking a missed opportunity for vaccination. The development of combination vaccines will circumvent this problem and increase compliance and vaccination coverage rates.
Related ArticlesImmunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.Eur J Pediatr. 2007
Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.
Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, Beckers F, Descamps D, Willems P. Eur J Pediatr. 2007 Aug; 166(8):857-64. Epub 2007 May 31.
Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.Vaccine. 2003
Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, et al. Vaccine. 2003 Sep 8; 21(25-26):3593-600.
Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.Ann Acad Med Singapore. 2007
Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
Lim FS, Han HH, Jacquet JM, Bock HL. Ann Acad Med Singapore. 2007 Oct; 36(10):801-6.
Review DTaP-IPV/Hib vaccine (Pentacel).Paediatr Drugs. 2008
Review DTaP-IPV/Hib vaccine (Pentacel).
Dhillon S, Keam SJ. Paediatr Drugs. 2008; 10(6):405-16.
Review Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).Expert Rev Vaccines. 2009
Review Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).
Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Expert Rev Vaccines. 2009 Jun; 8(6):663-78.
Combination vaccines.J Glob Infect Dis. 2011
Combination vaccines.
Skibinski DA, Baudner BC, Singh M, O'Hagan DT. J Glob Infect Dis. 2011 Jan; 3(1):63-72.
The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.BMC Infect Dis. 2010
The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
Chatterjee S, Rego SJ, D'Souza F, Bhatia BD, Collard A, Datta SK, Jacquet JM. BMC Infect Dis. 2010 Oct 15; 10:298. Epub 2010 Oct 15.
Review Vaccination greatly reduces disease, disability, death and inequity worldwide.Bull World Health Organ. 2008
Review Vaccination greatly reduces disease, disability, death and inequity worldwide.
Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, et al. Bull World Health Organ. 2008 Feb; 86(2):140-6.
To
top
•
Home
Show
map | Diseases | Vaccination
| Chronic disease | Medicine
| Pregnancy
| Heat & Sunburn | Cold | Security
| Useful tips | Faq
| News
TraveldoctorOnline 2001 •
Disclaimer • webmaster
